Control of Myosin motor activity and Actin filament translation by alteration of Assay Reducing Potential by Nalabotu, Siva Krishna
Marshall University
Marshall Digital Scholar
Theses, Dissertations and Capstones
2009
Control of Myosin motor activity and Actin
filament translation by alteration of Assay Reducing
Potential
Siva Krishna Nalabotu
nalabotu@marshall.edu
Follow this and additional works at: http://mds.marshall.edu/etd
Part of the Fluids and Secretions Commons, Medical Biochemistry Commons, Musculoskeletal
System Commons, and the Nanotechnology Commons
This Thesis is brought to you for free and open access by Marshall Digital Scholar. It has been accepted for inclusion in Theses, Dissertations and
Capstones by an authorized administrator of Marshall Digital Scholar. For more information, please contact zhangj@marshall.edu.
Recommended Citation
Nalabotu, Siva Krishna, "Control of Myosin motor activity and Actin filament translation by alteration of Assay Reducing Potential"
(2009). Theses, Dissertations and Capstones. Paper 123.
 TITLE 
 
Control of Myosin motor activity and Actin filament translation by 
alteration of Assay Reducing Potential 
By 
Siva Krishna Nalabotu B.V.Sc. & A.H. 
A thesis submitted to the 
Graduate faculty of the Department of Biology 
at 
Marshall University  
In partial fulfillment of the requirements for the degree 
of 
Master of Science 
 
 
 
Committee: 
_____________________________ Dr. Eric R Blough, Thesis adviser 
_____________________________ Dr. David Mallory, Committee member 
_____________________________ Dr. Bin Wang, Committee member 
 
 
 
06-10-2009 
Summer 2009 
Marshall University, Huntington, WV 
      
 
ABSTRACT 
The use of biomolecular motors for nanotechnological applications has been 
impaired by an inability to control biomolecular motor activity in a temporal fashion. 
Previous data has suggested that myosin activity can be modulated by inducing 
changes in the degree of myosin oxidation.  The hypothesis of this study is that myosin 
motor activity can be regulated by altering the amount of antioxidants and reducing 
agents present in assay solution. To test this hypothesis we systematically altered the 
concentration of reducing agents and examined the effects of these changes on 
myosin-dependent actin filament translation. Our findings indicate that myosin activity 
can be controlled over several on-off cycles in a controlled fashion by varying the 
amount of antioxidants and reducing agents in the assay medium. This strategy if 
further developed may lead to new ways to control myosin motor activity in 
bionanotechnological devices.  
(Total words 140) 
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CHAPTER 1 
 
INTRODUCTION 
 
Biomolecular motors are cellular machines that are involved in the contraction of 
muscles, cell movement and the transport of cargo molecules within cells [1]. 
Nanobiotechnology is a young and rapidly evolving field of research at the cross roads 
of biotechnology and nano science that is considered one of the key technologies of the 
21st century.  A long-term goal of nanobiotechnology is the utilization of biomolecular 
motors for controlled cargo carriers such as liposomes to be carried on a chip, with 
applications in sorting, separation, purification or assembly of materials.  
 
Biomolecular motors use the hydrolysis of adenosine triphosphate (ATP) to 
perform mechanical work with a remarkable degree of efficiency [2].  In the cell, 
biomolecular motors perform a wide variety of transport functions suggesting that they 
may someday be useful for the development of novel biomedical devices.  There are 
two classes of biomolecular motors: linear and rotary.  Linear motors include the myosin 
and kinesin motors while the rotary motors include the F0-F1 ATP synthase [3].  Among 
the linear motor type, myosin plays an important role in the contraction of muscles and 
in the transport of molecular cargo within cells.  The transport of cargo by myosin occurs 
along actin filaments.  Actin filaments are made up of glomerular actin (G-actin) 
subunits that are arranged in a head-to-tail fashion [4].  Recent work has demonstrated 
the potential use of biomolecular motors for the construction of actuators and 
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transporters capable of transporting micrometer and nanometer-sized objects like 
streptavidin coated beads and DNA molecules [3].  Other research in this field has been 
centered on developing suitable biocompatible substrates capable of supporting myosin 
activity [5].  While progress in these areas has been exciting, the application of 
biomolecular motors for nanotechnological applications has been hampered by an 
inability to accurately control motor activity.  
 
In an effort to control the activity of biomolecular motors, several different 
approaches have been utilized over the past few years including (1) the engineering of 
Zn2+ binding sites into kinesin motors and using the modulation of Zn2+ availability to 
govern the on / off state of the motor [6] , (2) the use of photo-activated ATP in an effort 
to modulate motor activity by altering the amount of ATP available for hydrolysis [7]  and 
(3) varying the temperature of the external environment surrounding the biomolecular 
motor to take advantage of the relationship between temperature and enzyme activity 
[8]. Although each approach has shown promise to control protein motor activity, these 
methods have yet to clearly demonstrate the ability to reversibly modulate motor activity 
over several cycles of activation.  
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Purpose 
 
The purpose of this research is to develop the means to temporally control actin 
filament motility across a motor patterned surface. To fulfill this purpose we will examine 
how the presence and absence of reducing agents affects the ability of the myosin 
motor to translate actin filaments. The overall hypothesis of this study is that myosin 
motor activity can be regulated by altering the amount of antioxidants and reducing 
agents present in assay solution.  
 
Specific Aims 
 
Protein molecular motors such as the actin-myosin system are natural nano-
machines that convert chemical energy directly into mechanical work. Our long-range 
goal is to use molecular motors for new biomedical applications. The ability to control 
the activity of molecular motors in an external environment is currently lacking.  Without 
better mechanisms of motor control the use of these machines for applied purposes is 
significantly hampered.  The objective of this study is to investigate the possibility of 
controlling molecular motor activity by altering the chemical composition of the buffer 
that the motor resides in. The working hypothesis of this study is that myosin motor 
activity can be regulated by altering the amount of antioxidants and reducing agents 
present in assay solution. To test this hypothesis two specific aims will be pursued: 
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Specific aim #1 
 
To determine if absence of reducing agents has an effect on myosin motor activity in the 
in vitro motility assay. 
Hypothesis 
The absence of reducing agents will have a significant effect on myosin motor 
activity.  
 
Specific aim #2 
 
To investigate if myosin motor activity can be cyclically controlled by altering the 
concentration of reducing agents in the assay medium 
Hypothesis 
Manipulation of reducing agent concentration can be used to cyclically control 
myosin motor activity.  
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CHAPTER 2 
 
REVIEW OF LITERATURE 
 
Introduction 
 A review of the pertinent literature concerning the present study will be presented 
in the following chapter.  The following areas will be addressed: 1) nano technology and 
nanobiotechnology: potential applications to mankind, 2) Structure and function of motor 
proteins, 3) Structure of the actomyosin motor system and, 4) Use of protein biomotors 
for nanotechnological applications. 
 
Nanotechnology and nanobiotechnology: potential applications to mankind 
 
Richard Feynman is widely credited for establishing the field of nanotechnology. 
Much of this credit arises from his famous talk “There’s plenty of room at the bottom”  
(American Physical Society: 1959) [9]. Initial progress in the field of nanotechnology 
was slow as it not until the 1980s that the scanning tunneling microscope and atomic 
force microscope were developed which allowed the manipulation and observation of 
single molecules. Since then, progress in the nanosciences has been rapid and has 
resulted in the ability of scientists to manipulate matter at its most fundamental level. 
For example, the development of the atomic force microscope has allowed researchers 
to individually pattern 35 xenon atoms to spell out the word “IBM” [10]. Similarly, other 
devices such as the atomic force microscopy now make it possible for scientists to 
probe the atomic structure of DNA [11]. Key goals of nanotechnology are to develop 
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new molecular treatments for disease, new types of manufacturing processes and new 
materials that would increase productivity while diminishing the effects of man on the 
environment.  
 
Nanobiotechnology is defined as a field that applies nanoscale principles and 
techniques to understand and transform biosystems or use biological principles and 
materials to create new devices and systems integrated from the nanoscale [12].  Many 
of the most basic processes of life occur at the nanoscale suggesting that 
understanding the design of biological systems can be useful for the development of 
novel nanodevices and systems.  For example, developing a better understanding of 
how a cell is designed and interacts with its environment may help researchers to 
develop new types of biological or chemical sensors.  Such devices could have use in 
many fields including diagnostics, DNA separation and in the development of new 
nanomaterials that could be used imaging [13].  Recent advances in the field of 
nanobiotechnology have enabled higher sensitivity in detecting cancer cells and 
proteins, new methods of tumor imaging, and new materials e.g. liposomes, that could 
be used to deliver medicine or other types of molecules for the treatment of cancer [14]. 
 
Structure and function of motor proteins 
 
Motor proteins convert chemical energy derived from the hydrolysis of ATP into 
mechanical energy [2]. Bionanomotors are used in muscle contraction and for the 
transport of cargo molecules within cells [15]. There are two types of motor systems: 
linear and rotary motor systems.  Linear systems operate in a linear fashion while rotary 
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motors produce rotary motion [3].  Most of the current research in the field of these 
motor proteins has centered on linear motor proteins. There are three linear motor 
proteins in the cell: myosin motors which move on actin filaments and the kinesin and 
dynein motors which use microtubules [3].   
 
Compared to kinesin and dynein, the actomyosin motility system may be 
advantageous for applications that involve the transport of materials. For example, the 
actomyosin system enables faster transportation (up to 10 times faster with muscle 
myosin II) [16] and the capacity to move heavier loads given its ability to generate 
higher amount of force [3].  
 
Actin-myosin motor system 
 
Muscle fibers are actually composed of large single cells that had been formed 
from many separate cells that have fused together.  The bulk of the muscle fiber 
cytoplasm is made up of myofibrils.  These myofibrils contract in the presence of ATP 
and calcium and in doing so generate the force used to produce movement. The 
structural unit of the myofibril is the sarcomere. Each sarcomere contains an anisotropic 
band that is bound by two isotropic bands. The anisotropic band is called the A-band; 
the isotropic band is called the I-band [17].  In the center of the A band, there is a lighter 
region known as the H-zone or H-band.  The myofibrils in turn are composed of two 
proteinaceous structures called myofilaments.  One filament is termed the thick filament 
and is about 11 nm in diameter[18]  whereas the other filament is called the thin filament 
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and is 5 nm in diameter [19].  Thick filaments are made up of several hundred myosin 
molecules.  
 
Within the cell there are many types of myosin such as myosin I, myosin II, 
myosin V and others[20].  Among these myosin types, myosin II is the most well known. 
Myosin II is known as a conventional myosin. It is present in all non-plant eukaryotic 
cells[4]. In the cells, myosin II plays an important role in muscular contraction, 
cytokinesis, and vesicle transport[21]. 
 
Structure of myosin filament 
 
 
Figure 1. Structure of the myosin filament 
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Myosin is an actin-based molecular motor (molecular weight ~ 520 kDa). It 
consists of two large pear-shaped domains (S1) attached by their stems to a long tail 
(Figure 1). It is made of six subunits. There are two heavy chains of about 220 kDa in 
the head region. There is a regulatory domain in the region of the myosin head 
immediately behind the globular catalytic domain consisting of four light chains. The 
light chains are arranged in the form of pairs and one pair is called as essential light 
chain while the other pair is known as the regulatory light chain. These light chain pairs 
also used to support the neck portion of the myosin molecule and are useful to form the 
core of the thick filament [19].  
 
Heavy meromyosin (HMM) is obtained by the chymotrypsin digestion of the 
myosin molecule. HMM contains two globular structures termed the S1 domain. The 
structure of the S1 domain has been determined using x-ray crystallographic techniques 
[18]. Within the S1 domain are two clearly defined morphological domains, which have 
been termed the “motor domain” and the “regulatory domain”. The large cleft at the front 
in the motor domain is the actin binding site. The smaller cleft on the side of the motor 
domain is the ATP-binding site or the nucleotide binding site. The ATP binding site 
contains ATPase activity and is responsible for the hydrolysis of the ATP into adenosine 
di-phosphate (ADP) and inorganic phosphate (Pi). The energy released from the 
hydrolysis of ATP causes the power stroke of myosin which in turn is responsible for the 
translation of the actin molecule [19]. Because the S1 domain (myosin head) contains 
the ATP and actin-binding sites, the myosin head can generate force (Figure 2). The 
head joins with another heavy chain to form a long α-helical coiled-coil tail (Figure 1).   
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Figure 2. Myosin showing the actin and ATP binding sites 
 
Adopted from (http://www.biomed.miami.edu/pharm/faculty_Szczesna.html) 
 
Structure of actin filament 
 
Actin is a very common structural component of the eukaryotic cell [22].  Actin is 
also an important component of the cytoskeleton.  Actin filaments are found in the 
sarcomere where they play an important role in muscle contraction by binding with the 
myosin filaments.  Actin typically exists in two different states: globular actin (G-actin) 
and filamentous actin (F-actin) [19].  G-actins can polymerize and form polar F-actin. F-
actin is a two-start right-handed helix, with a crossover every 36 nm consisting of 13-14 
actin monomers and has a fast growing (plus) and slow growing (minus) end [19].  
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Figure 3. Three dimensional structure of actin 
 
 
Use of protein biomotors for nanotechnological applications 
 
Currently research activity concerning the use of protein biomotors is primarily 
centered on the utilization of myosin motors which move on actin filaments and kinesin 
and dynein motors which move on microtubules.  As the force producing capacity of 
myosin motors is high (10 times that of the kinesin motors) the utilization of myosin 
motors may provide a mechanical advantage over that realized with the kinesin and 
dynein motors. The development of nanodevices that could be powered by protein 
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biomotors has been hampered due to a current failure to overcome three important 
problems:  
(1.) The immobilization and patterning of protein biomotors onto a surface in such 
a fashion that still allows enzyme function,  
(2.) An inability to develop a reliable and reversible means of coupling molecular 
cargo in such a way that it could be transported by protein biomotor systems,  
(3.) The ability to temporally controlled protein biomotor activity. 
 
Efforts to develop biomotor immobilization and patterning 
 
Although very useful for the study of biomotor function, the application of 
biomolecular motors for nanotechnological applications has been hindered by limitations 
in the ability to accurately control the motion of the moving filaments as they travel 
across the substrate surface. Given this restraint, several approaches have been 
developed and utilized over the past few years to create well defined patterns of motor 
proteins across a micro patterned surface. For example, motor protein binding tracks 
have been produced by aligned poly (tetrafluoroethylene) films on glass, micrometer 
scale grooves, and nanoimprinting lithography [23] [24]. However, in most cases, the 
motility is not entirely confined to the tracks. To achieve confinement of the motility of F-
actin filaments on myosin motors, trimethylchlorosilane (TMCS) has been investigated. 
An advantage of this surface type is its ability to be patterned by electron beam 
lithography or by exposure to ultraviolet (UV)/ ozone treatment [25].  
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Methods to load molecular cargo for transport using protein biomotor systems 
 
Limited work has been done in the area of cargo loading and transport in 
biological nano systems since it is often viewed as the next step after directional control 
as discussed above. Efforts in this area to date have focused on binding synthetic nano 
elements to specific proteins, and the interaction of specific biological materials, such as 
biotin and streptavidin. This strategy has been quite successful as it has been 
demonstrated that microtubules and actin filaments functionalized with biotin can be 
used for the transport of streptavidin coated polystyrene beads, DNA molecules and 
quantum dots [24, 26]. A disadvantage of these methods is that the cargo has to be pre-
functionalized and the “cargo loading” is largely irreversible in nature.  
 
A promising and versatile method is the use of filaments that are coated with 
antibodies or single-stranded DNA oligonucleotides or any other type of biochemical 
affinity capture molecule specific for the cargo to be transported [27, 28]. Several 
research groups have demonstrated the transportation of materials, including DNA [29], 
viruses[26], and myoglobin and BSA [28], through specific bioaffinity capture materials.  
However, unloading these cargoes is still limiting the application of this technology.    
 
Methods to modulate protein biomotor activity  
 
Currently there are no efficient methods to control biomotor activity that are 
reversible in nature. In an effort to overcome this limitation, several approaches have 
been developed and utilized over the past few years include (1) the engineering of Zn2+ 
14 
 
      
 
binding sites into the kinesin motors and using the modulation of Zn2+ availability to 
govern the on / off state of the motor [6],  (2) the use of photo-activated ATP in an effort 
to modulate motor activity by altering the amount of ATP available for hydrolysis [7] and 
(3) varying the temperature of the external environment surrounding the biomolecular 
motor to take advantage of the relationship between temperature and enzyme activity 
[8].   
 
Initial efforts to control motor activity have been centered on the genetically 
engineering new regulatory domains e.g. a Zn+2 binding site, into the native biomotor 
structure [6]. Although this type of approach has demonstrated the cyclical activation and 
inactivation of microtubule motility by kinesin it appears that this type of control system 
exhibits a high degree of variability as the microtubule velocity is not constant after one 
period of cycling. Why the velocity and percentage of moving microtubules might vary 
between cycles is not known but may be related to alterations in the way the kinesin 
motor is structured after the incorporation of the new regulatory domain. Current efforts 
in this field are now investigating how other modifications of the kinesin protein may 
affect motor activity.  
 
In addition to genetic engineering approaches, the use of photo-activated ATP for 
controlling kinesin activity has also been investigated [7]. In this approach, caged ATP 
which can be activated and inactivated by exposure to ultra violet (UV) radiation is used.  
It is based on the premise that exposure of the caged ATP to UV radiation will result in 
the controlled liberation of ATP from the caged compound. The released ATP in turn 
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can be used by the kinesin motors to induce microtubule movement. The efficiency of 
this approach and its effects on microtubule movement is dependent upon the 
concentration of ATP, caged ATP, ADP, kinesin activity, the quantum yield of the 
uncaging reaction, temperature, light intensity, and the mutual dependencies between 
these parameters. Similar to research using engineered constructs that are responsive 
to divalent metal concentration, this approach has yet to demonstrate the ability to cycle 
motor activity over time.  
 
It is well known that temperature can affect enzyme activity. Recent efforts have 
demonstrated that temperature can be used to modulate myosin activity [8]. In these 
experiments, thermal heating and cooling pads have been incorporated into a flow cell 
that is used to house the motility assay. By controlling the flow of electricity to these 
pads, the temperature of the flow cell can be varied.  Although this study showed that 
changes in temperature can be used to modulate the motility of F-actin filaments the 
temperature extremes needed to inhibit myosin activity are likely to be incompatible 
over time with currently used motility substrates. In addition, this procedure also 
requires extensive modification of the flow cell.   
 
In summary, a review of the current literature demonstrates progress in the area 
of motor activity control has been made but that limitations still exist. The major 
limitation in this area of inquiry is the inability to cyclically control motor activation and 
inactivation. This thesis project has been designed to specifically address this gap. 
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Summary 
 Nanotechnology is the study of molecules or atoms at the nanoscale while 
nanobiotechnology integrates the investigation of biological systems with the 
nanosciences.  A long term goal of nanobiotechnology is the utilization of biomolecular 
motors for controlled cargo manipulation on a chip, with applications in sorting, 
separation, and the purification or assembly of materials. Biomolecular motors exhibit 
the ability to convert chemical energy into mechanical energy with high efficiency. For 
nanotechnological purposes, most research investigating biomolecular motors has used 
either myosin or kinesin. The incorporation of biomolecular motors into nanodevices will 
require the ability to surmount three challenges: the development of appropriate 
surfaces capable of maintaining motor activity, the reversible coupling of cargo to motor 
driven structures and the ability to modulate motor activity over time. Progress in this 
latter area has been steady however the ability to cycle biomolecular motors on and off 
over several cycles has yet to be achieved. This thesis will address this gap in our 
understanding.  
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CHAPTER 3 
 
 
Control of myosin motor activity and actin filament translation by alteration of 
assay reducing potential* 
 
 
 
 
 
 
 
 
 
 
 
 
*The results of this thesis have been formatted for publication purposes. 
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Abstract 
 
The study of biomolecular motors represents a rapidly and progressing field of 
nanobiotechnology. Here, we present a simple method for controlling the activity of 
myosin and movement of actin filaments on a myosin coated surface. Our findings 
indicate varying the amount of anti oxidants in the assay buffer can be used to alter 
filament motility. This data suggest that antioxidants may be useful for the selective 
control of myosin II activity. 
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Introduction  
 
Bionanomotors such as myosin and kinesin use the hydrolysis of adenosine 
triphosphate (ATP) to perform mechanical work with a remarkable degree of efficiency. 
In the cell, these motors perform a wide variety of transport functions suggesting that 
they may someday be useful for the development of novel new biomedical devices [15, 
30].  Recent work has demonstrated the potential use of bionanomotors for the 
construction of actuators and transporters capable of transporting micrometer and 
nanometer-sized objects [3].   While this progress have been exciting, the application of 
biomolecular motors for nanotechnological applications has been hampered by an 
inability to accurately control motor activity. 
  
In an effort to overcome this limitation, several approaches have been developed 
and utilized over the past few years including Zn2+ binding to genetically engineered 
kinesin motors[6], photo-activated ATP[7], local anesthetics [31] and varying the 
temperature of the motility chamber[8].  Although promising, these control systems have 
yet to demonstrate the ability to reversibly modulate motor activity over several cycles of 
activation.  Here we investigate the potential of altering the concentration of reducing 
agents as a means of controlling myosin activity.  Our results demonstrate that myosin 
motor activity can be accurately and reversibly controlled by varying amounts of 
reducing agents within the assay buffer.   
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Materials and methods 
 
Surface preparation  
Glass cover slips (Cat. No. 12-540A, Fisher) were functionalized with 
nitrocellulose (2% colloidin in isoamyl acetate, Okenshoji Co, Japan) using solution 
deposition and soft-baking at 40ºC for 1 hr as detailed previously [32].  
 
Motility assays  
The procedures of the motility assay have been described previously [33].  
Briefly, HMM was extracted from the back and leg muscle of a rabbit and purified. HMM 
was prepared by limited digestion of myosin with α-chymotrypsin [32].  Actin was 
extracted in the monomeric form from an actin acetone powder of chicken breast 
muscle [34] and then the polymerized actin filaments were labeled with 
tetramethylrhodamine-phalloidin (Molecular Probes, Inc., OR, USA).  Flow cells were 
constructed from a No. 2 cover slip using strips of double sided 90 µm thick tape 
(Nichiban Co, Japan).  The flow cell was filled with 120 µg/ml HMM diluted in the assay 
buffer which contained 25 mM KCl, 2 mM MgCl2, 0.2 mM CaCl2 and 25 mM imidazole at 
pH 7.0 and incubates for 5 min.  Bovine serum albumin (0.1 % BSA in water) was used 
to prevent the filaments from nonspecifically binding to the surface.  After a 5 min 
incubation, the flow cell was washed with the assay buffer, and 0.25 µg/ml labeled 
filaments in assay buffer supplemented with 10 mM dithiothreitol (DTT), 4.5 mg/ml D(+)-
glucose, 0.22 mg/ml glucose oxidase and 0.036 mg/ml catalase was introduced into the 
flow cell.  Motility was activated by exchange of actin loading solution with assay buffer 
containing 1.5mM adenosine-5`-triphosate (ATP).  Motility assays were performed at 
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room temperature (20-23°C) and observed under fluorescence microscope (Olympus 
BH-2, Japan) with a 100X objective (1.3 N.A., oil-immersion; UVFL100, Olympus, 
Japan) through a CCD camera (Hamamatsu Photonics C2400, Japan) and a monitor.  
 
Cycling experiments 
To determine the effect of varying the concentration of reducing agents on 
filament movement in vitro motility experiments were performed in the absence and 
presence of reducing agents (10 mM DTT, 4.5 mg/ml D (+)-glucose, 0.22 mg/ml glucose 
oxidase and 0.036 mg/ml catalase).  To examine the potential of using reducing agents 
to reversibly alter filament movement, filament motility was assayed before and after the 
addition of motility buffer with and without antioxidants.  Up to three cycles of buffer 
exchange were tested.  To investigate the contribution that each of the different 
reducing agents may have on myosin activity, motility assays were performed using 
standard conditions after the omission of an individual compound.  
 
Determination of filament velocity  
Images of the moving actin filaments were digitally recorded onto a computer 
(Dell, Dimension 4300).  The velocity of actin filament movement was analyzed using 
software (Image J) as outlined by the manufacturer (http://rsb.info.nih.gov/ij/). Image 
frames were collected at 0.5 Hz for 30 s and used for the determination of sliding 
velocity.  The sliding of all filaments in the images was obtained by tracking the leading 
end of each filament in each frame.  
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Dot blot analysis for nitro tyrosine and nitro cysteine  
 The procedure for the dot blot analysis to identify the oxidative modification of 
nitro cysteine and nitro tyrosine residues of myosin has been described previously [35] 
For these experiments, HMM was exposed to fluorescent light for one minute to mimic 
the conditions of the actual experiment. In a parallel set of experiments, GODCAT, DTT, 
or GODCAT+DTT were excluded from the assay medium prior to the exposure of the 
HMM to fluorescent light. Once exposed, 5 µL of protein [120 µg/mL] from each tube 
was spotted onto a Hybond nitrocellulose membrane (Piscataway, NJ).  Membranes 
were air-dried for 20 min and blocked in 5 % BSA prepared in Tris-buffered saline 
containing 0.5% Tween 20 (TBS-T) for 1 h at room temperature. Membranes were 
incubated in primary antibody for 1 hour at room temperature and washed three times in 
TBS-T. The following primary antibodies and dilutions were used: Nitro-Tyrosine (# 
9691, Cell signaling technology) and Anti-S-Nitroso-Cysteine (SNO-Cys) (# N5411, 
Sigma Aldrich) which are added at the dilutions of 1:1000 in 5% BSA prepared in TBS-
T. Immuonoreactivity was detected following incubation with a horseradish peroxidase-
labeled (HRP) IgG secondary antibody and reaction with enhanced chemiluminescence 
(ECL) Western blotting detection reagent (# RPN 2106V, GE Health care). The 
exposure time was adjusted to keep the integrated optical densities within a linear and 
nonsaturated range. Band signal intensity was quantified by densitometry using a 
flatbed scanner (Epson Pefection 3200 PHOTO) and Imaging software (AlphaEaseFC). 
At least four independent experiments were performed for each condition.     
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Oxidized Protein Analysis  
Oxidized myosin protein was evaluated using the OxyBlot™ Oxidized Protein 
Detection Kit (Chemicon International, Monterrey, Nuevo León, México) according to 
manufacture specifications. Band signal intensity was quantified by densitometry using 
a flatbed scanner (Epson Perfection 3200 PHOTO) and Imaging software 
(AlphaEaseFC). At least four independent experiments were performed for each 
condition.     
 
Statistical analysis  
Results are presented as mean ± SEM.  All comparisons were performed by 
Students t-tests or a two-way analysis of variance (ANOVA) with post hoc analysis 
where appropriate.  For all comparisons the alpha level was set a priori at P≤ 0.05.   
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Results   
Effect of reducing agent concentration on actin filament motility  
Once introduced into the flow cell, the F-actin bound rigidly to the myosin 
immobilized on the cover slip. Similar to previous work by our laboratory and others [36] 
the addition of assay buffer containing 1.5mM ATP, 10 mM dithiothreitol, 4.5 mg/ml D 
(+)-glucose, 0.22 mg/ml glucose oxidase and 0.036 mg/ml catalase stimulated the 
continuous movement of the actin filaments with an average velocity in the range of 
2.62 ± 0.07 µm/s at 20 – 23 °C (Figure 4 a).  The average percentage of moving 
filaments under these conditions was 84 ± 2% (Figure 4 b).  
 
When the buffer was exchanged with an assay medium which contained 1.5mM 
ATP in the absence of reducing agents, the actin filament movement quickly came to a 
stop (Figures 4a, 4b).  After observation for 5 minutes under these conditions, the assay 
buffer was exchanged once again to one which contained antioxidants.  Upon addition 
of assay buffer with antioxidants the filaments began to move.  Within a few seconds 
the average velocity of the actin filaments was 2.64±0.06 µm/s while the percentage of 
moving filaments was 74±2%.  This cycle was repeated two additional times.  During 
the third cycle the average velocity of filament movement was 2.76±0.06 µm/s and 
percentage of moving filaments was 73±2%.  Taken together, these experiments 
demonstrate that actin filament motility can be controlled by altering the presence or 
absence of reducing agents in the motility buffer (Figures 5a, 5b).   
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To determine the individual effect that DTT and the oxygen scavengers 
contribute to the on/off cycle, motility assays were performed using standard conditions 
after omission of individual compound.  Compared to that observed using the 
“complete” motility buffer, the average velocity and percentage of moving actin filaments 
in assay medium lacking in DTT was unchanged (2.62 ± 0.07 µm/s vs. 2.27 ± 0.05 
µm/s; 84 ± 2% vs. 85 ± 2 % (Figures 3a, 3b). Conversely, the average velocity and 
percentage of moving actin filaments in assay medium lacking glucose oxidase and 
catalase was significantly reduced (2.62 ± 0.07 µm/s vs. 1.25 ± 0.08 µm/s, (P < 0.05); 
84 ± 2% vs. 25±4 %, (P < 0.05) (Figures 3a, 3b). Taken together, these data suggest 
that the omission of DTT has less of an effect on actin filament motility than the oxygen 
scavengers, glucose oxidase and catalase. 
  
To better understand the effects of the antioxidants on myosin motors, we next 
analyzed the effects of fluorescent light on myosin modification using dot blotting and 
oxyblot analysis (Figures 8, 9, 10). Compared to control conditions, the omission of 
GODCAT or GODCAT plus DTT resulted in a significant decrease (50- 60%; P < 0.05) 
in the oxidative modification of myosin.  The data suggest that myosin needs to exhibit a 
basal amount of oxidative modification to attain optimal activity.  
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Discussion 
A current limitation for the use of bionanomotors in the development of 
nanodevices is an inability to control motor activity.  Here we examine if altering the 
amount of reducing equivalents can be used as a means of controlling actin filament 
movement.  For these experiments we varied the concentration of DTT, glucose 
oxidase and catalase in the motility buffer and determined the effect of these alterations 
on actin filament movement.  Our data demonstrate the actin motility can be halted by 
the omission of antioxidants from the motility buffer (Figs 4a, 4b) and then restored 
again by the addition of antioxidants to the motility chamber (Figures 5a, 5b). 
Importantly, the restoration of filament velocity and the percentage of motile filaments 
did not change between three cycles of activation and inhibition. To our knowledge this 
finding has not been reported before. Indeed, although previous work using either 
genetically engineered motor proteins or temperature modulation have failed to 
demonstrate an ability to maintain or restore motor activity following inhibition  [6, 8, 37].  
 
The mechanism(s) by which alterations in the amount of DTT, glucose oxidase or 
catalase may affect myosin activity are currently unknown.  Previous research has 
demonstrated that myosin ATPase activity can be activated and inactivated by chemical 
oxidation and reduction.  In these studies ATPase activity could be inhibited by the 
addition of hydrogen peroxide and then restored later by the addition of the antioxidants 
like cysteine or glutathione [38].  It is thought that the inactivation of myosin by hydrogen 
peroxide may arise from the oxidation of sulphydral [(-SH) thiol] groups to form 
disulphide linkages (-SS-).  The addition of cysteine or glutathione, in turn act as 
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reducing agents to restore the thiol groups and enzyme function. In another study, it 
was shown that the modification of myosin sulphydral groups causes ATPase activity to 
follow a bell shaped curve [39]. Our data demonstrate a reduced myosin activity with 
decreased myosin modification. Whether further increases in myosin activity with 
modification beyond that observed in the present study is currently unclear. 
Nonetheless, our data clearly show that oxidative modifications in the myosin molecule 
can be used to regulate myosin activity in an on- and off-fashion.  
 
Conclusion  
We demonstrate that the inclusion or absence of glucose oxidase, catalase and 
DTT in the myosin motility buffer can be used to control myosin activity during the in 
vitro motility assay. Unlike other methods that involve metal chelation [37], the use of 
local anesthetics [31] or caged-ATP [7], this technique appears to be a simple 
alternative that does not require expensive equipment.  These findings may be useful to 
develop new means of controlling myosin motility.  
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Figure 4 
 
 
 
  
Figure 4. a). Velocity of actin filaments in assay buffer with and without antioxidants 
b). Percentage of moving actin filaments in assay buffer with and without antioxidants 
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Figure 5 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 a). Cyclical variation in the average velocity of filaments with and without 
antioxidants in the assay medium. b). Cyclical Variation in the percentage of motile 
filaments with and without antioxidants in the assay medium 
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Figure 6
 
Figure 6 a). Average velocity of actin filaments at different levels of oxidation by 
removing the reducing agents in the assay medium. b). Percentage of motile actin 
filaments at different levels of oxidation by removing the reducing agents in the assay 
medium. * Significantly different from amount present in assay medium containing 
antioxidants. † Significantly different from amount present in assay medium lacking 
DTT. Ω Significantly different from assay medium lacking GODCAT. 
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Figure 7 a 
 
Figure 7 a). Displacement of actin filaments during an interval of 5 s after the initial 
movement. The paths of two filaments measured with Image-J software are shown. 
Cropped images with yellow tracks show the displacement of the filaments with an 
interval of 5 sec. 
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Figure 7 b 
 
Figure 7 b). Complete stop of the actin filaments after exchanging the buffer without 
antioxidants. 
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Figure 7 c 
 
Figure 7 c). Restart of the actin filaments after exchanging the buffer with reducing 
agents. The paths of two filaments measured with Image- J software are shown. 
Cropped images with yellow tracks show the displacement of the filaments with an 
interval of 5 sec 
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Figure 8 
 
 
                               Exposed to fluorescent light for one minute 
 
Figure 8. Effect of solution reducing potential on protein nitrosylation. * Significantly 
different from positive control. 
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Figure 9 
 
 
                                  Exposed to fluorescent light for one minute 
 
Figure 9. Effect of solution reducing potential on the degree of nitrocysteine residues 
present in the assay medium. * Significantly different from positive control. 
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Figure 10 
 
 
 
                            Exposed to fluorescent light for one minute 
 
Figure 10. Effect of solution reducing potential on the degree of protein carbonylation.  
* Significantly different from positive control. 
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CHAPTER 4 
 
Conclusions 
 
In this thesis document our recent research concerning the use of reducing 
agents to control the activity of myosin ATPase and actin filament movement during the 
in vitro motility assay is presented. Here we present a simple way to control the motor 
activity of myosin motors in a switch on/off fashion. To accomplish this, we modified the 
internal environment of the motility assay medium without any change in the average 
velocity of actin filaments, by introducing and removing the antioxidants from the assay 
medium with the aid of motility assay buffer. We demonstrate that alterations in the 
concentration of reducing agents can be used to control actin filament movement across 
a myosin coated substrate. Unlike other control methods such as use of genetically 
engineered motor constructs, photo activated ATP or modulating enzyme activity by 
altering environmental temperature, this technique appears to be a simple alternative 
that does not require expensive equipment and obviates the use of metal chelation or 
genetical engineering. Our findings may be useful in future nanodevices that use 
myosin bionanomotors. These devices are imagined to load the bionanomotors with the 
cargo carriers like liposomes at one place and unload the molecules from these 
liposomes at a different location. To realize this, we need the motors to be controlled 
temporally which is possible if they are controlled in a switch on/off fashion. So we 
conclude that the development of nanodevices can be realized with the results we got, if 
they are incorporated into a suitable nanodevice. 
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Future Directions 
 
To expand upon the present research future research efforts could be undertaken to:  
1. To develop a means for the transport of cargo molecules in a directed and 
controlled fashion. For example, it is evident that the actin filaments can be 
loaded and unloaded with the cargo carriers like liposomes (unpublished 
observation). To enable this transport in a controlled fashion, the motility of the 
actin filaments should be controlled precisely so that the loading and unloading 
the cargo at the specific location of interest could be achieved.  
 
2. To incorporate the use of bionanomotors into a device that could be used to sort 
different molecules from one another. To achieve this goal, polydimethylsiloxane 
(PDMS) molded channels could be integrated with biomolecular motors such as 
myosin. Coupling a motor control system into this device may allow the ability to 
stop and start motility at pre-designated areas where molecular cargo could be 
picked up or dropped off.  
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APPENDIX 
Standard in vitro motility assay 
 
Nitrocellulose coated cover glass: 0.2% Collodion in Isoamyl acetate  
Assay buffer: 25mM KCl, 2mM MgCl2, 0.2mM CaCl2, and 25mM Imidazole, pH 7.0 
 BSA: 1mg/ml  
HMM: 120μg/ml  
Actin solution(X100):  
95μL Assay buffer                                                                
1μL 1mM DTT  
1μL 0.216mg/ml Glucose oxidase,  
1μL 0.036mg/ml Catalase  
1μL 4.5mg/ml Glucose                                  
1μL 0.25ug/ml RP-labeled F-actin  
 
ATP solution(X100):  
95μL Assay buffer  
1μL 1mM DTT  
1μL 0.216mg/ml Glucose oxidase,  
1μL 0.036mg/ml Catalase  
1μL 4.5mg/ml Glucose  
1μL 1.5mMATP  
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Procedure 
 
 Assemble a flow cell with slide glass, nitrocellulose coated cover glass, and double 
adhesive tape.  
1. Add 8μL of HMM to the flow cell and incubate for 5min  
2. Block with 25μL of BSA and incubate for 5min. (capillary action and using kimwipe to 
introduce the solution)  
3. Wash with 25μL of Assay buffer.  
4. Add 25μL of F-actin labeled with Rhodamine phalloidin solution.  
5. Observe under the fluorescent microscope. Add 25μL of ATP solution. Non-binding 
Actin will be washed off, and Binding actin will start to move.  
6. Adjust the sensitivity of CCD camera and the intensity of fluorescent. (Rhodamine will 
be fluoresced under the green light)  
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Results 
Table 1.Cyclical variation of the average velocity (µm/s) of the actin filaments 
 
  Start 1 Stop 1 Start 2 Stop 2 Start 3 Stop 3 
  2.94 0.00 2.91 0.00 3.61 0.00 
  2.73 0.00 3.12 0.00 3.64 0.00 
  2.79 0.00 3.51 0.00 3.09 0.00 
  2.32 0.00 2.86 0.00 2.80 0.00 
  3.41 0.00 2.80 0.00 2.61 0.00 
  3.39 0.00 2.65 0.00 3.62 0.00 
  3.64 0.00 2.22 0.00 2.35 0.00 
  3.64 0.00 3.49 0.00 3.41 0.00 
  3.33 0.00 3.48 0.00 2.97 0.00 
  3.72 0.00 2.70 0.00 2.99 0.00 
  2.83 0.00 2.60 0.00 2.53 0.00 
  3.89 0.00 3.07 0.00 3.06 0.00 
  2.92 0.00 2.70 0.00 3.49 0.00 
  3.06 0.00 3.76 0.00 2.75 0.00 
  2.51 0.00 3.85 0.00 3.16 0.00 
  2.91 0.00 2.83 0.00 2.42 0.00 
  4.11 0.00 2.37 0.00 3.87 0.00 
  3.11 0.00 3.11 0.00 4.07 0.00 
  3.66 0.00 3.25 0.00 1.88 0.00 
  3.16 0.00 2.98 0.00 3.66 0.00 
  3.88 0.00 3.59 0.00 3.19 0.00 
  3.52 0.00 2.89 0.00 3.26 0.00 
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  3.42 0.00 2.72 0.00 3.15 0.00 
  4.03 0.00 3.18 0.00 3.45 0.00 
  4.22 0.00 2.65 0.00 2.95 0.00 
  1.79 0.00 2.61 0.00 2.40 0.00 
  1.97 0.00 2.32 0.00 2.42 0.00 
  1.83 0.00 2.14 0.00 1.75 0.00 
  2.36 0.00 1.51 0.00 2.16 0.00 
  1.64 0.00 2.40 0.00 2.29 0.00 
  2.53 0.00 2.11 0.00 2.25 0.00 
  1.74 0.00 2.57 0.00 2.25 0.00 
  1.48 0.00 2.05 0.00 2.38 0.00 
  2.03 0.00 2.55 0.00 2.72 0.00 
  2.53 0.00 2.18 0.00 2.94 0.00 
  1.98 0.00 1.67 0.00 2.47 0.00 
  2.09 0.00 1.49 0.00 2.27 0.00 
  2.79 0.00 2.95 0.00 2.42 0.00 
  1.76 0.00 1.94 0.00 1.83 0.00 
  1.93 0.00 2.08 0.00 1.83 0.00 
  2.11 0.00 2.79 0.00 2.83 0.00 
  2.01 0.00 1.82 0.00 1.36 0.00 
  2.62 0.00 2.44 0.00 2.12 0.00 
  2.50 0.00 2.35 0.00 1.74 0.00 
  2.40 0.00 2.51 0.00 2.56 0.00 
  2.21 0.00 2.39 0.00 2.77 0.00 
  1.97 0.00 2.21 0.00 2.39 0.00 
  2.27 0.00 2.68 0.00 2.89 0.00 
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  2.46 0.00 1.65 0.00 2.47 0.00 
  1.87 0.00 2.33 0.00 2.52 0.00 
  2.32 0.00 2.02 0.00 2.74 0.00 
  2.02 0.00 2.32 0.00 2.53 0.00 
  2.48 0.00 1.73 0.00 2.38 0.00 
  2.57 0.00 2.27 0.00 2.94 0.00 
  2.27 0.00 2.31 0.00 3.96 0.00 
  2.22 0.00 2.97 0.00 2.76 0.00 
  2.66 0.00 2.60 0.00 2.44 0.00 
  2.02 0.00 2.77 0.00 2.81 0.00 
  2.66 0.00 3.03 0.00 2.17 0.00 
  2.28 0.00 2.39 0.00 2.66 0.00 
  1.67 0.00 2.45 0.00 2.97 0.00 
  2.85 0.00 2.16 0.00 2.60 0.00 
  2.88 0.00 3.08 0.00 2.46 0.00 
  2.55 0.00 2.37 0.00 2.91 0.00 
  2.98 0.00 2.70 0.00 3.35 0.00 
  2.75 0.00 2.55 0.00 3.03 0.00 
  2.94 0.00 2.88 0.00 3.53 0.00 
  2.10 0.00 2.80 0.00 2.84 0.00 
  2.60 0.00 3.41 0.00 3.29 0.00 
  2.43 0.00 2.50 0.00 2.42 0.00 
  2.43 0.00 2.70 0.00 2.69 0.00 
  1.83 0.00 2.87 0.00 2.86 0.00 
  2.10 0.00 4.41 0.00 2.76 0.00 
  2.08 0.00 2.81 0.00 2.85 0.00 
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  2.63 0.00   
 
2.99 0.00 
    
 
  
 
  
 N 75.00 75.00 74.00 74.00 75.00 75.00 
Mean 2.62 0.00 2.64 0.00 2.76 0.00 
STDEV 0.66 0.00 0.55 0.00 0.55 0.00 
SEM 0.08 0.00 0.06 0.00 0.06 0.00 
Maximum 4.22 0.00 4.41 0.00 4.07 0.00 
Minimum 1.48 0.00 1.49 0.00 1.36 0.00 
Total 196.26 0.00 195.10 0.00 206.88 0.00 
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Table 2.Cyclical variation of the motility percentage of the actin filaments 
 
  Start 1 Stop 1 Start 2 Stop 2 Start 3 Stop 3 
  90.00 0.00 81.58 0.00 75.00 0.00 
  96.23 0.00 83.33 0.00 78.57 0.00 
  88.10 0.00 83.33 0.00 73.91 0.00 
  82.86 0.00 73.33 0.00 78.05 0.00 
  88.89 0.00 77.78 0.00 82.86 0.00 
  73.33 0.00 80.00 0.00 72.73 0.00 
  94.74 0.00 69.23 0.00 88.24 0.00 
  71.43 0.00 80.00 0.00 57.14 0.00 
  78.95 0.00 54.55 0.00 60.00 0.00 
  70.59 0.00 66.67 0.00 75.00 0.00 
  84.52 0.00 69.33 0.00 68.66 0.00 
  85.71 0.00 77.27 0.00 77.63 0.00 
  84.71 0.00 75.34 0.00 69.32 0.00 
  86.25 0.00 68.89 0.00 71.79 0.00 
  84.00 0.00 74.73 0.00 73.24 0.00 
N 15.00 15.00 15.00 15.00 15.00 15.00 
Average 84.02 0.00 74.36 0.00 73.48 0.00 
STDEV 7.69 0.00 7.71 0.00 7.87 0.00 
SEM 2.06 0.00 2.06 0.00 2.10 0.00 
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Table 3.Variation in the average velocity of the filaments at various levels of the 
oxidation 
  Reduced Without DTT Without GODCAT Oxidized 
  2.94 2.23 1.08 0.00 
  2.73 2.18 1.31 0.00 
  2.79 2.09 0.87 0.00 
  2.32 2.09 0.79 0.00 
  3.41 2.72 0.95 0.00 
  3.39 2.72 1.15 0.00 
  3.64 2.32 1.57 0.00 
  3.64 1.73 1.40 0.00 
  3.33 1.92 1.31 0.00 
  3.72 1.88 1.32 0.00 
  2.83 2.70 1.21 0.00 
  3.89 2.30 1.19 0.00 
  2.92 3.03 1.41 0.00 
  3.06 2.61 1.85 0.00 
  2.51 2.29 1.52 0.00 
  2.91 2.49 1.49 0.00 
  4.11 2.03 1.07 0.00 
  3.11 2.34 1.59 0.00 
  3.66 2.79 0.95 0.00 
  3.16 4.01 1.50 0.00 
  3.88 2.70 1.58 0.00 
  3.52 2.48 1.55 0.00 
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  3.42 1.98 1.12 0.00 
  4.03 2.18 1.64 0.00 
  4.22 2.02 0.00 0.00 
  1.79 2.19 0.00 0.00 
  1.97 2.19 0.00 0.00 
  1.83 1.73 0.00 0.00 
  2.36 2.60 0.00 0.00 
  1.64 2.03 1.60 0.00 
  2.53 2.03 1.53 0.00 
  1.74 2.06 1.18 0.00 
  1.48 2.45 1.09 0.00 
  2.03 2.15 1.90 0.00 
  2.53 2.65 1.84 0.00 
  1.98 1.90 1.41 0.00 
  2.09 1.57 2.24 0.00 
  2.79 2.78 1.71 0.00 
  1.76 1.62 2.10 0.00 
  1.93 2.21 1.34 0.00 
  2.11 1.88 1.43 0.00 
  2.01 2.03 1.85 0.00 
  2.62 3.16 1.81 0.00 
  2.50 1.80 1.22 0.00 
  2.40 1.63 1.56 0.00 
  2.21 1.94 0.00 0.00 
  1.97 2.53 0.00 0.00 
  2.27 1.78 0.00 0.00 
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  2.46 2.16 0.00 0.00 
  1.87 1.79 1.75 0.00 
  2.32 2.08 1.49 0.00 
  2.02 2.19 1.82 0.00 
  2.47 2.03 2.26 0.00 
  2.57 2.32 1.83 0.00 
  2.27 2.70 1.71 0.00 
  2.22 2.38 1.75 0.00 
  2.66 2.84 1.24 0.00 
  2.02 2.43 1.58 0.00 
  2.66 2.00 1.35 0.00 
  2.28 2.36 1.85 0.00 
  1.67 2.15 1.67 0.00 
  2.85 2.98 1.38 0.00 
  2.88 2.65 1.33 0.00 
  2.55 2.61 1.44 0.00 
  2.98 2.07 1.55 0.00 
  2.75 2.93 1.53 0.00 
  2.94 1.92 1.34 0.00 
  2.10 3.05 0.00 0.00 
  2.60 2.67 0.00 0.00 
  2.43 2.95 1.48 0.00 
  2.43 2.05 1.78 0.00 
  1.83 1.46 1.77 0.00 
  2.10 1.87 0.00 0.00 
  2.08 1.95 0.00 0.00 
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  2.63 1.38 2.63 0.00 
        0.00 
N 75.00 75.00 75.00 75.00 
Mean 2.62 2.28 1.25 0.00 
STDEV 0.66 0.45 0.65 0.00 
SEM 0.08 0.05 0.08 0.00 
Max 4.22 4.01 2.63 0.00 
Min 1.48 1.38 0.00 0.00 
Total 196.26 170.71 93.75 0.00 
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Table 4.Variation in the motility percentage of the filaments at various levels of 
the oxidation 
 
  Reduced Without DTT Without GODCAT Oxidized 
  90.00 80.00 17.65 0.00 
  96.23 70.00 25.58 0.00 
  88.10 82.35 33.33 0.00 
  82.86 85.00 19.05 0.00 
  88.89 80.56 22.22 0.00 
  73.33 92.31 0.00 0.00 
  94.74 100.00 31.71 0.00 
  71.43 100.00 32.43 0.00 
  78.95 71.43 35.00 0.00 
  70.59 84.62 3.23 0.00 
  84.52 86.49 33.33 0.00 
  85.71 85.71 42.86 0.00 
  84.71 88.00 48.48 0.00 
  86.25 85.19 10.34 0.00 
  84.00 83.33 13.64 0.00 
N 15.00 15.00 15.00 15.00 
Average 84.02 85.00 24.59 0.00 
STD DEV 7.69 8.36 14.01 0.00 
SEM 2.06 2.23 3.74 0.00 
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STATISTICAL ANALYSIS 
One Way Analysis of Variance                 Wednesday, February 25, 2009, 3:44:58 PM 
Data source: Average velocities of the actin filaments in different cycles. 
Normality Test:         Passed   (P = 0.064) 
Equal Variance Test: Passed (P = 0.170) 
Group Name   N  Missing Mean STD Dev SEM  
Start-1   75 0 2.617 0.657 0.0758  
Start-2                   74         0  2.636 0.549 0.0638  
Start-3                    75 0 2.758 0.545 0.0629  
Source of Variation DF   SS   MS    F    P   
Between Groups 2 0.881 0.440 1.283 0.279  
Residual 221 75.837 0.343    
Total 223 76.718     
The differences in the mean values among the treatment groups are not great enough 
to exclude the possibility that the difference is due to random sampling variability; there 
is not a statistically significant difference  (P = 0.279). 
Power of performed test with alpha = 0.050: 0.091 
The power of the performed test (0.091) is below the desired power of 0.800. 
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Less than desired power indicates you are less likely to detect a difference when one 
actually exists. Negative results should be interpreted cautiously. 
One Way Analysis of Variance                 Wednesday, February 25, 2009, 3:49:42 PM 
Data source: Motility percentage of the actin filaments in different cycles. 
Normality Test: Passed (P = 0.057) 
Equal Variance Test: Passed (P = 0.989) 
 
Group Name  N  Missing Mean STD Dev SEM  
Start-1 15 0 84.020 7.694 1.987  
Start-2 15 0 74.357 7.711 1.991  
Start-3 15 0 73.476 7.870 2.032  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 1026.558 513.279 8.527 <0.001 
Residual 42 2528.290 60.197    
Total 44 3554.848     
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The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
Power of performed test with alpha = 0.050: 0.940 
All Pair wise Multiple Comparison Procedures (Tukey Test): 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
Start-1 vs. start-3 10.544 3 5.263 0.002 Yes  
Start-1 vs. start-2 9.662 3 4.823 0.004 Yes  
Start-2 vs. start-3 0.882 3 0.440 0.948 No  
One Way Analysis of Variance                                Friday, April 10, 2009, 9:54:47 AM 
Data source: Variability in the velocity of the actin filaments with the variability of the 
level of the antioxidants. 
Normality Test: Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on RanksFriday, April 10, 2009, 
9:54:47 AM 
Data source: Variability in the velocity of the actin filaments with the variability of the 
level of the antioxidants. 
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Group N  Missing  Median    25%      75%     
Reduced 75 0 2.525 2.093 2.939  
Without DTT 75 0 2.190 1.981 2.614  
Without oxygen  
scavengers 75 0 1.406 1.084 1.662  
 
Oxidized 75 0 0.000 0.000 0.000  
H = 235.314 with 3 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than 
would be expected by chance; there is a statistically significant difference (P = <0.001) 
To isolate the group or groups that differ from the others use a multiple comparison 
procedure. 
All Pair wise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q P<0.05   
Reduced vs. Oxidized 14197.000 18.898 Yes   
Reduced vs. without OSS 8985.500 11.961 Yes   
Reduced vs. Without DTT 1805.500 2.403 No   
Without DTT vs. Oxidized 12391.500 16.495 Yes   
 
59 
 
      
 
Without DTT vs. Without  
OSS 7180.000 9.557 Yes 
Without OSS vs. Oxidized 5211.500 6.937 Yes   
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
Abbreviations: OSS (Oxygen Scavenging System- Glucose oxidase, catalase in the 
medium of glucose) 
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One Way Analysis of Variance Friday, April 10, 2009, 10:01:57 AM 
Data source: Variability in the percentage of motile actin filaments with the variability of 
the level of the antioxidants. 
Normality Test: Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on RanksFriday, April 10, 2009, 
10:01:57 AM 
Data source: Variability in the percentage of motile actin filaments with the variability of 
the level of the antioxidants. 
Group N  Missing  Median    25%      75%     
Reduced 15 0 84.706 79.925 88.690  
Without DTT 15 0 85.000 81.005 87.622  
Without OSS 15 0 25.581 14.639 33.333  
Oxidized 15 0 0.000 0.000 0.000  
H = 50.033 with 3 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than 
would be expected by chance; there is a statistically significant difference (P = <0.001) 
To isolate the group or groups that differ from the others use a multiple comparison 
procedure. 
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All Pair wise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q P<0.05   
Without DTT vs. Oxidized 555.500 8.213 Yes   
Without DTT vs. without OSS 345.500 5.108 Yes   
Without DTT vs. Reduced 1.000 0.0148 No   
Reduced vs. Oxidized 554.500 8.198 Yes   
Reduced vs. without OSS 344.500 5.093 Yes   
Without oxygen vs. Oxidized 210.000 3.105 No   
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
Abbreviations: OSS (Oxygen Scavenging System- Glucose oxidase, catalase in the 
medium of glucose). 
 
One Way Analysis of Variance Thursday, June 18, 2009, 9:29:47 AM 
Data source: Nitro tyrosine 
Normality Test: Passed (P = 0.470) 
Equal Variance Test: Passed (P = 0.149) 
Group Name  N  Missing Mean     Std Dev SEM  
 HMM            6 0           27.433     3.448 1.408  
 HMM+F 6 0           23.533     3.564 1.455  
 W/O  
 GODCAT  6 0                  13.283      2.581 1.054  
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 W/O DTT 6 0                  24.850      4.400 1.796  
 W/O AO 6 0               10.850        0.565 0.231  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 4 1320.582 330.146 32.407 <0.001  
Residual 25 254.685 10.187    
Total 29 1575.267     
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference  (P = <0.001). 
Power of performed test with alpha = 0.050: 1.000 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
HMM vs. W/O AO 16.583 5 12.727 <0.001 Yes  
HMM vs. W/O GODCAT  14.150 4 10.859 <0.001 Yes  
HMM vs. HMM+F 3.900 3 2.993 0.107 No  
HMM vs. W/O DTT 2.583 2 1.983 0.173Do Not Test  
W/O DTT vs. W/O AO 14.000 4 10.744 <0.001 Yes  
W/O DTT vs. W/O GODCAT 11.567 3 8.877 <0.001 Yes  
W/O DTT vs. HMM+F 1.317 2 1.010 0.482Do Not Test  
HMM+F vs. W/O AO 12.683 3 9.734 <0.001 Yes  
HMM+F vs. W/O GODCAT 10.250 2 7.866 <0.001 Yes  
W/O GODCAT  vs. W/O AO2.433 2 1.867 0.199 No  
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A result of "Do Not Test" occurs for a comparison when no significant difference is 
found between two means that enclose that comparison.  For example, if you had four 
means sorted in order, and found no difference between means 4 vs. 2, then you would 
not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 1 (4 vs. 3 and 3 vs. 2 are 
enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the enclosed means is a procedural 
rule, and a result of Do Not Test should be treated as if there is no significant difference 
between the means, even though one may appear to exist. 
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One Way Analysis of Variance Thursday, June 18, 2009, 10:41:48 AM 
Data source: Nitro cysteine 
Normality Test: Passed (P = 0.056) 
Equal Variance Test: Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on RanksThursday, June 18, 2009, 
10:41:48 AM 
Data source: Nitro cysteine 
Group N  Missing  Median    25%      75%    
HMM 6 0 24.700 21.800 31.000  
HMM+F 6 0 24.850 21.600 28.200  
W/o  
GODCAT 6 0 11.150 10.900 11.300  
W/o DTT 6 0 26.450 23.100 26.600  
W/o AO 6 0 12.900 12.700 13.200  
 
H = 22.368 with 4 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than 
would be expected by chance; there is a statistically significant difference  (P = <0.001) 
To isolate the group or groups that differ from the others use a multiple comparison 
procedure. 
 
 
65 
 
      
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison                               Diff of Ranks          q P<0.05   
 W/o DTT vs W/o GODCAT 112.000 5.194 Yes   
 W/o DTT vs W/o AO 76.000 3.524 No   
 W/o DTT vs HMM+F 7.500 0.348 Do Not Test   
 W/o DTT vs HMM 4.500 0.209 Do Not Test   
 HMM vs W/o GODCAT 107.500 4.985 Yes   
 HMM vs W/o AO 71.500 3.316 Do Not Test   
 HMM vs HMM+F 3.000 0.139 Do Not Test   
 HMM+F vs W/o GODCAT 104.500 4.846 Yes   
 HMM+F vs W/o AO 68.500 3.177 Do Not Test   
 W/o AO vs W/o GODCAT 36.000 1.669 No   
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
A result of "Do Not Test" occurs for a comparison when no significant difference is 
found between the two rank sums that enclose that comparison.  For example, if you 
had four rank sums sorted in order, and found no significant difference between rank 
sums  4 vs. 2, then you would not test 4 vs. 3 and 3 vs. 2, but still test 4 vs. 1 and 3 vs. 
1 (4 vs. 3 and 3 vs. 2 are enclosed by 4 vs. 2: 4 3 2 1).  Note that not testing the 
enclosed rank sums is a procedural rule, and a result of Do Not Test should be treated 
as if there is no significant difference between the rank sums, even though one may 
appear to exist. 
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One Way Analysis of Variance Thursday, June 18, 2009, 10:44:20 AM 
Data source: Oxyblot 
Normality Test: Passed (P = 0.863) 
Equal Variance Test: Passed (P = 0.563) 
Group Name  N  Missing Mean Std Dev SEM  
 HMM          6 0 25.133 2.448 1.000  
 HMM+F 6 0 27.483 2.079 0.849  
W/o GODCAT 6 0 14.100 1.103 0.450  
 W/o DTT 6 0 23.017 2.388 0.975  
 W/o AO 6 0 10.233 2.433 0.993  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 4 1329.895 332.474 71.800 <0.001  
Residual 25 115.763 4.631    
Total 29 1445.659     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference  (P = <0.001). 
Power of performed test with alpha = 0.050: 1.000 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
Comparisons for factor:  
 
  
67 
 
      
 
Comparison Diff of Means p q P P<0.050  
HMM+F vs. W/o AO 17.250 5 19.636 <0.001 Yes  
HMM+F vs. W/o GODCAT13.383 4 15.234 <0.001 Yes  
HMM+F vs. W/o DTT 4.467 3 5.084 0.004 Yes  
HMM+F vs. HMM 2.350 2 2.675 0.070 No  
HMM vs. W/o AO 14.900 4 16.961 <0.001 Yes  
HMM vs. W/o GODCAT 11.033 3 12.559 <0.001 Yes  
HMM vs. W/o DTT 2.117 2 2.409 0.101 No  
W/o DTT vs. W/o AO 12.783 3 14.551 <0.001 Yes  
W/o DTT vs. W/o GODCAT8.917 2 10.150 <0.001 Yes  
W/o GODCAT vs. W/o AO 3.867 2 4.401 0.005 Yes  
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     WORK EXPERIENCE 
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 Oct 2007 - Dec 2007: Poultry pathologist, Srinivasa hatcheries, Vijayawada, 
India. 
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people about how to improve the productivity of live stock, control of 
diseases by vaccination, attending various vetero legal cases like 
toxicities and performing postmortem to identify the cause of death, 
making people aware of various zoonotic diseases and community 
outreach programs.  
 
      EDUCATION 
 Jan 2008- Present (Grade:3.56/4.0) 
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      TESTS 
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       PUBLICATIONS 
1.  Application of PAMAM dendrimers for use in bionanomotor systems 
Madhukar Kolli, B Scott Day, Kevin M. Rice, Hideyo Takatsuki, Kazahiro 
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of assay reducing potential Siva K Nalabotu, Eric R. Blough (In 
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bundle-myosin motor system Hideyo Takatsuki, Hideyuki Tanaka, 
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       PROFESSIONAL MEMBERSHIPS 
 Association of Young Scientists                           Jan 2008-present 
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 AAAS (American Association for the advancements in Science).  
 
      NANO TECHNOLOGY TECHNIQUES 
 Purification of actin from chicken skeletal muscle. 
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 Epi fluorescent microscopy. 
 Analysis of data using win DVD creator project software. 
 Making PDMS molds and silicon masters. 
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 MOLECULAR BIOLOGY TECHNIQUES 
 SDS–PAGE 
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 Protein extraction & Purification from muscle samples 
 
      ANIMAL MODELS   
 Trained to handle animals in research as per IACUC guidelines. 
 Experienced with F344XBN F1 Aging rat model, Gerbils and Obese 
Syndrome X Zucker rat model.  
 Rat Hind limb Suspension model of Muscle Atrophy; Skeletal Muscle Stretch. 
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aspects of rats. 
 
       MICROSCOPIC TECHNIQUES  
 Light microscopy  
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       CURRENT PROJECTS 
 Master’s Thesis Project: Control of myosin motor activity and actin filament 
translation by alteration of assay reducing potential, PI: Eric R Blough, Ph. D 
(Fall 2008). Marshall University, Huntington, WV. 
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Investigator: Eric R Blough, PhD Marshall University, Huntington, WV (Spring 
2008). 
 
        PREVIOUS RESEARCH EXPERIENCE 
 June 2005-Oct 2005: “Earn while you learn” poultry project in conjunction with 
the department of poultry science. Primary Investigator: Dr. Ch. Srilatha, 
Ph.D. College of Veterinary Science, Tirupati. 
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       PRESENTATIONS 
 Spring 2008: 1. “Use of erythrocyte ghost cells as cargo carriers”.  
                      2. “Metabolic syndrome - pros and cons”  
                      Marshall University, College of Science. 
 
 Fall 2008: “Use of liposomes for controlled delivery of nano cargo in in-vitro              
motility assays”, Marshall University, College of Science. 
 
    AWARDS 
 Jan 2008 onwards: Marshall University, NSFEPSCoR #9871948 graduate 
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  COMPUTING AND STATISTICAL SOFTWARE 
 Well-acquainted with MS Office,  
 Adobe® Photoshop,  
 Adobe® Acrobat,  
 Sigma Stat®,  
 Endnote®,  
 BIOPAC® Systems. 
 Analysis with Win DVD creator project software. 
 Alpha ease software, 
 Well acquainted with IMAGE J analysis. 
 
   COMMUNITY SERVICE AND OTHER ACTIVITIES 
 July 2007: Participated in National Social Service (NSS) animal health camps 
and gynecology camps to treat infertility in animals. 
 Aug 2007 - Sep 2007: Participated in free animal health camp to treat 
ailments of animals. 
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